Integer Holdings Corp (ITGR) Secures Long-Term Supply Agreement with Neuros Medical

December 6, 2017 8:07 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Integer Holdings Corporation (NYSE: ITGR) today announced that its subsidiary, Centro de Construccion de Cardioestimuladores del Uruguay S.A. (CCC), has signed a ten-year supply agreement with Neuros Medical, Inc. (Neuros). Under the new agreement, CCC will be the sole supplier of key “Products” for Neuros’ Altius® System. The Products include the implantable generator and related external devices (Clinician Programming Wand, Patient Controller, and Charger).

Neuros is currently conducting its pivotal IDE clinical study to evaluate its patented Altius® System High Frequency Nerve Block technology for the management of post-amputation pain (including post-amputation pain, phantom limb-pain, residual limb pain, and stump pain).

“We are honored to be awarded this long-term supply agreement with Neuros, a company that shares our vision to enhance the lives of patients worldwide through life-changing technology,” said Tony Gonzalez, president of Integer’s Cardiac Rhythm Management and Neuromodulation product line. “This agreement highlights Integer’s breadth of capabilities to support customers with design, development and manufacturing of advanced technologies and systems. By leveraging our fully customizable platforms and our systems expertise, we will help Neuros bring its therapy to market quickly and cost-effectively, while maintaining the utmost quality and reliability. We look forward to continuing our relationship with the Neuros team as they progress through their current clinical study and beyond.”

Tom Wilder, Neuros Medical’s president and chief executive officer, said, “We are excited to have Integer as a strategic partner and supplier in our long-term plans to utilize our High Frequency Nerve Block technology to address unmet medical needs involving chronic nerve pain. This includes continued enrollment in and completion of our pivotal IDE clinical study to investigate the use of the Altius System for treatment of post-amputation pain.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments